Commentary

Video

Dr Carlo-Stella on Updated Results on RG6234 Activity in R/R Multiple Myeloma

Carmelo Carlo-Stella, MD, PhD, discusses updated results from a phase 1 dose-escalation study of subcutaneous and intravenous RG6234 in relapsed/refractory multiple myeloma.

Carmelo Carlo-Stella, MD, PhD, Department of Biomedical Sciences, Humanitas University, Department of Oncology and Hematology, IRCCS Humanitas Research Hospital, discusses updated results from a phase 1 dose-escalation study (NCT04557150) of subcutaneous (SC) and intravenous (IV) RG6234 in relapsed/refractory multiple myeloma.

The study evaluated the safety and pharmacokinetics of RG6234, a GPRC5DxCD3 T-cell engaging bispecific antibody, in patients with relapsed or refractory multiple myeloma who have no sufficient available or tolerable standard-of-care treatments.

Data presented at the 2022 ASH Annual Meeting demonstrated that RG6234 was highly effective when administered either intravenously or subcutaneously, Carlo-Stella states. The overall response rate (ORR) was 71.4% in the IV cohort and 63.6% in the SC cohort. Notably, over 50% of patients in the IV cohort displayed a very good partial response or better.

Additionally, 71.4% of patients who achieved complete remission (CR) became minimal residual disease (MRD) negative, Carlo-Stella continues. These data support the efficacy of RG6234 and indicate the potential for achieving long-term, durable responses with this agent.

Related Videos
John L. Marshall, MD
Petros Grivas, MD, PhD
Noopur S. Raje, MD
Atish D. Choudhury, MD, PhD
Benjamin Levy, MD
Paolo Tarantino, MD
Sujith Samarasinghe, MD
Suzanne Trudel, MSc, MD
Consuelo Bertossi, MD
Michael R. Grunwald, MD, FACP